Dako Sponsors European Pathology Congress for Second Straight Year

GLOSTRUP, Denmark, Aug. 29, 2014

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, is again a major sponsor of the annual European Congress of Pathology.

The 2014 ECP is being held Aug. 30 - Sept. 3 at the ExCeL Centre in London. Agilent will feature a variety of its pathology and genomics solutions, including several new products.

Throughout the symposium, delegates will be able to see live demonstrations of the company's newest pathology solution, Dako Omnis, at Booth 6. Dako Omnis automates both IHC and ISH processes, allowing entire patient cases to be processed simultaneously, which enables results for both IHC and ISH to be delivered at the same time-a real breakthrough for pathology labs. Agilent will present the first fully automated ALK testing with the IQFISH hybridization buffer for Dako Omnis, enabling efficient, flexible and high-quality FISH workflow on the Dako Omnis platform.

ClearSeq AML, the latest product in a series of next-generation sequencing cancer research panels, will also be unveiled at this year's ECP. This panel provides comprehensive coverage of mutations and enables swift progression of sample processing in less than a day. The AML gene panel will be followed in the coming months by the release of additional research panels for lung, lymphoma and colorectal cancer and a comprehensive cancer panel.

In addition to Dako Omnis and ClearSeq AML, Agilent will be demonstrating all of its complete pathology and genomics solutions, including NGS, IHC, ISH, histostaining and connectivity. Attendees can visit a fluorescence microscopy room to see some of the newest technologies, such as the Agilent high-resolution SureFISH probes, and the Dako quality reagents and pharmDx™ kits, such as HER2 IQFISH pharmDx™. The booth will also offer information on Agilent's next generation sequencing (NGS) solution, with the industry-leading HaloPlex and SureSelect products.

The exhibit hall will be open Aug. 30 - Sept. 2, and booth staff will be available each day for product demonstrations and discussion with congress attendees.

In addition, two important scientific events will be held by Agilent in conjunction with this year's ECP.

On Monday, Sept. 1, a scientific symposium titled "Current Challenges in Breast Cancer Diagnosis: New Guidelines and Implementation in Clinical Practice" will be held from 1 p.m. - 2:30 p.m. in Capital Suite Room 7/12. Topics will include:

  • Implementation of guidelines in clinical practice - the EU experience (Dr. Ian Ellis Nottingham, U.K.)
  • How to handle triple-negative breast cancers (Dr. J Reis-Filho, Memorial Sloan-Kettering, U.S.), and
  • Implementing new technologies and future perspectives (Dr. Kenneth Bloom, Clarient Diagnostics, U.S.)

On Tuesday, Sept. 2, Agilent will present a special evening seminar titled "Introducing NGS into the Pathology Workflow," from 7 - 9 p.m. at ibis Styles London ExCeL Hotel in the HMS President room. Participants will receive an introduction to NGS technology and workflows, as well as an overview of how NGS disease research panels can yield deeper profiles of tumor samples for clinical research.

"We are extremely pleased to serve as a major sponsor of ECP once again," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics business. "Being a part of this congress and having valuable dialogue with all of the attendees is important to us."

For the first time, the company has partnered with the Rarer Cancers Foundation (RCF) and the ESP to host a 5 km charity run to raise funds for RCF. Participation is free, and Agilent will make a donation to RCF for each runner. All participants are also encouraged to collect pledges for RCF from colleagues, family and friends. RCF is a UK-based charity that works closely with politicians, NICE and NHS England to ensure that people with rarer cancers have access to the best possible services across the United Kingdom.

Attendees at the ECP are pathologists and other key decision-makers in the field of pathology from primarily European hospitals, private laboratories and the government.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Agilent acquired Dako in 2012, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at www.agilent.com and information about Dako products is available at www.dako.com.

In September 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. On Aug. 1, 2014, the company's electronic measurement business began operating as Keysight Technologies, Inc., a wholly owned subsidiary. The separation is expected to be completed in early November 2014.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent's electronic measurement business; future revenues, earnings and profitability; the future demand for the company's products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces include those detailed in Agilent's filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information.

# # #


Victoria Wadsworth-Hansen
Dako Products and Solutions for Pathology
+45 29336980

Maia Fredtoft Søchting
Media and Press
+45 25461083